Member Info for violindog

Hi Drac, I hope you are enjoying the sunshine 🤣

I think Scancell has a bright future ...either as a take out target ...partial sale ...or as a go it alone entity. We have had some terrific appointments recentely from the management team to the clinical appointment today. If SCOPE continues to produce excellent results I do hope to see my 50p target ASAP. Its personal target... a reflection on my finances timeframe etc. I hope other LTHs are able to enjoy the journey further and exit at points beyond 50p.

It's interesting to look at the latest performance from BMS released in their earnings call last Friday.

Extract below ...

" Robust financial performance with significant net earnings growth.

Leadership in immuno-oncology and strategic acquisitions bolstering the product pipeline.

Challenges include patent expirations and intense competition.

Opportunities in expanding global markets and potential for new drug approvals.

Bristol-Myers Squibb Co (NYSE:BMY), a pioneer in the discovery, development, and marketing of drugs for critical therapeutic areas, has reported a robust financial performance in its latest 10-Q filing dated July 26, 2024. The company has showcased a significant increase in net earnings, reporting $1,684 million for the three months ended June 30, 2024, compared to a loss in the previous year. This financial muscle underscores BMY's ability to invest in research and development, strategic acquisitions, and market expansion, setting a solid foundation for its SWOT analysis.

Chester18....re your 9:02 ..spot on ..I don't know how BMS could ignore this opportunity.

Excellent RNS

Dr Nermeen Varawalla, newly appointed Chief Medical Officer, Scancell, added: "I am thrilled to be joining Scancell at a pivotal phase in the Company's development, as it nears significant clinical milestones and inflection points. "

Sclp's SP has made some excellent progress of late ... ... coincidence it was timed just prior the latest RNS ?

Cash wise we are still in a relatively strong position for any negotiations and the indicators are pointing to groundbreaking trial results. On the back of these comments....How do you guys reckon the Registration trial will be funded ? It will be interesting to see what path is either taken or offered !!

ICB, i anticipated that the SP would build on yesterday's brilliant RNS. In my opinion the RNS basically told us the current trial is a sucess.

GF123, yes, a very odd reaction to a brilliant RNS.

Perhaps if we were told an "interested " party was going to fund the Registration trial we would have had a positive response from the market ??

Bobbust, if they want stock....lift the bid to 50 p and I will oblige 🙂

Good volume again today !

Amazing post by Chilltime, written elsewhere.....

"Those 500k sells that you call them are buys, the share price direction tells you that.

It’s not necessarily someone supplying a 500k lump.

EG

X puts in an order for 500k, the broker fills the order by whatever means including multiple smaller buys available in the market. Typically the relevant broker sits on the bid.

Once the order is filled whether it took hours or days, it gets reported to the market, typically mid price and in the unknown column.

It’s perfectly legitimate under the rules for orders over the typical market size to be reported once they are complete.

There is no fee for each buy hence you’ll see multiple apparently very small trades, it’s just a collection system for anything hitting the price.

If selling 1 mill, 2 mill etc to a buyer that approached them that trade would appear as that amount once it’s completed, often double printed, shares in shares out, sometimes triple.

As the price is rising it suggests buying in the market, order in, electronically sweeping up sells. Others buy (private investors) in rising prices. It all depends how many the buyer wants and what price they are willing to pay for them.

It could be 10 mill then stop or the start of a large stake with plans to acquire Scancell.

It’s not unreasonable to speculate a pharma is buying, given the patent cliffs for those in Melonoma sector with Scib so far blowing their treatments out of the water.

Scancell could in theory, steal a $1.5 bill market right from under their noses. If Scancell do that, they potentially have the cash firepower to enhance patent cliff treatments with their platforms to become the standard of care.

Redmile and Vulpes saw this coming long before the rest. If the data hits the mark (it should) other big funds wanting larger chunks are already waiting in the wings. Lindy mentioned that point in an interview.

Interesting times ahead for investors and cancer sufferers"

Thanks guys !!

WTP..." Ordinary trade executed as an SI "

I just wonder what SI stands for ?

All those multiple SI trades at 14:06... what are those ??

Purchased @ 14:53 pm @ 14:40p

6190 purchased but can't see it on LSE .

Hope you re-purchased .

I did the same the other day but bought leaving an odd munbered holding . Simply going to have to buy 6190 to get an even round number again.

OCD 🙂

EE, indeed , it needs a revision..... but let's hope we make their current valuation on this bull run we are enjoying 🙂. Getting nearer to my 50p target 🙂🤔

GF123, hope so 🙏

The spread showing ...10. 4% a bit miserable 😨... but great to have renewed interest. Funny old reflection on how life is....Scancell publish and present outstanding data at major conferences and the SP fails to budge...and then you get afew lines in a news print and we're off 😀

ICB, indeed, as far as I am concerned, the more the story is published why would any genuine shareholder be concerned ....it can only be a positive event.

We are seeing some nice sized trades recently 😀